Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck's Keytruda Lead Widens Over Competing Checkpoint Inhibitors

Executive Summary

CEO Ken Frazier had to argue the case that Merck has a diversified portfolio in yet another strong quarter for the PD-1 inhibitor Keytruda.


Related Content

BioMarin Is Carrying The Biggest Target On Its Back, Morningstar Says
New Products Soar And Old Stand Their Ground As Roche Heads Off Biosimilar Threat
Bristol Stuck In Waiting Game As Opdivo TMB Gamble Fails To Pay Off
First-Line Ovarian Cancer Approval Solidifies Lead For AstraZeneca's Lynparza
Roche's Tecentriq Becomes Second In PD-1/L1 Family To Gain First-Line Lung Cancer Approval
Merck Looks To Add Pneumonia To Zerbaxa Label; Market Value Not Clear
First In 10 Years, But Lenvima's First-Line Liver Label Could Be Challenged Soon
Merck's Stellar Keytruda Squamous Lung Cancer Data Refute Naysayers
Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense
Shingrix Seen Replacing Zostavax In EU & US as Shingles Standard Of Care


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts